Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2006

Linger J, Tyler JK. Global replication-independent histone H4 exchange in budding yeast. Eukaryot Cell. 2006;5(10):1780-7.

Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006;12(1):152-8.

Magro CM, Seilstad KH, Porcu P, Morrison CD. Primary CD20+CD10+CD8+ T-cell lymphoma of the skin with IgH and TCR beta gene rearrangement. Am J Clin Pathol. 2006;126(1):14-22.

Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006;5(1):61-6.

Rohan S, Tu JJ, Kao J, Mukherjee P, Campagne F, Zhou XK, et al. Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res. 2006;12(23):6937-45.

de Reyniès A, Geromin D, Cayuela J-, Petel F, Dessen P, Sigaux F, et al. Comparison of the latest commercial short and long oligonucleotide microarray technologies. BMC Genomics. 2006;7:51.

Chung KY, Morrone G, Schuringa JJ, Plasilova M, Shieh J-, Zhang Y, et al. Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer Res. 2006;66(24):11781-91.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-, Setlur S, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66(17):8337-41.

Breza TS, Zheng P, Porcu P, Magro CM. Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. J Cutan Pathol. 2006;33(7):522-8.

Seidman JD, Horkayne-Szakaly I, Cosin JA, Ryu HS, Haiba M, Boice CR, et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol. 2006;103(2):703-8.